Prof. Dr. Karim Fizazi (FR) defined non-metastatic castration-resistant prostate cancer (M0 CRPC) as a male patient with prostate cancer who had previous local treatment often; had prostate-specific antigen (PSA) relapse and then received androgen-deprivation therapy (ADT) or ADT with primary local treatment; and who is now progressing by PSA while on ADT.
